NCT07005557View on ClinicalTrials.gov

Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

1,244

Participants

Timeline

Start Date

June 15, 2025

Primary Completion Date

May 15, 2030

Study Completion Date

May 15, 2035

Conditions
Breast CancerAdjuvant Therapy
Interventions
DRUG

Chemotherapy

Chemotherapy options at physician's discretion: TC, EC-T(wP), or capecitabine.

DRUG

CDK4/6 Inhibitor

All patients will receive CDK4/6 inhibitor (abemaciclib/ribociclib/dalpiciclib/palbociclib)

DRUG

Endocrine therapy

Endocrine therapy (letrozole/anastrozole/exemestane)

All Listed Sponsors
lead

Fudan University

OTHER